Details checkedStrong evidenceCheckedcompany

ReSound Nexia

Also known as: Nexia, ReSound Nexia hearing aids, ReSound Nexia Auracast hearing aids

GN ReSound

Primary source

Company

GN ReSound

Program Type

Device

Modality

Prescription Hearing Aid

Stage

Marketed

Status

Marketed

Target Gene

—

Route / Mode

Professionally fitted hearing aids and CROS transmitters with Auracast-enabled wireless accessories

Confidence

91%

Status Confidence

Status confirmed

Evidence Strength

Strong evidence

Last Reviewed

2026-06-10

Geography

United States, Europe, Global

Population

adult, prescription-hearing-aid, receiver-in-canal, behind-the-ear, custom-hearing-aid, auracast, cros-compatible

Trial IDs

Mechanism

Prescription hearing-aid family built around Auracast broadcast-audio readiness, Bluetooth LE Audio connectivity, hearing-in-noise performance, and multiple styles including Micro RIE, RIE, BTE, custom devices, and CROS transmitters.

Indications

Hearing Loss Sensorineural Hearing Loss Single-Sided Deafness

Notes

Adds ReSound’s Auracast/Bluetooth LE Audio platform as a connectivity-defined prescription-hearing-aid family distinct from the newer Vivia AI-audio flagship.

Evidence & Sources

2 structured sources

company

Supports: canonicalName, company, mechanism, status, route, populationTags

Open

company

Supports: aliases, mechanism, route

Open

Key Events

2024-01-01

ReSound positioned Nexia as an Auracast-ready hearing-aid line with multiple styles and CROS support

Related Programs